4.4 Article

Risk Factors for Developing Thyroid-Associated Ophthalmopathy Among Individuals With Graves Disease

期刊

JAMA OPHTHALMOLOGY
卷 133, 期 3, 页码 290-296

出版社

AMER MEDICAL ASSOC
DOI: 10.1001/jamaophthalmol.2014.5103

关键词

-

资金

  1. National Eye Institute K23 Mentored Clinician Scientist Award [1K23EY019511]
  2. Blue Cross Blue Shield of Michigan Foundation [EY08976, EY011708, DK063121, EY016339, EY021197, EY007003]
  3. Research to Prevent Blindness
  4. Bell Charitable Foundation
  5. NATIONAL EYE INSTITUTE [F31EY007003, K23EY019511, R01EY011708, R01EY021197, R01EY008976, K23EY016339, P30EY007003] Funding Source: NIH RePORTER
  6. NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK092926, R01DK063121] Funding Source: NIH RePORTER

向作者/读者索取更多资源

IMPORTANCE Thyroid-associated ophthalmopathy (TAO) is a common and debilitating manifestation of Graves disease (GD). Presently little is known about factors that may increase the risk of developing TAO among patients with GD. OBJECTIVE To identify risk factors associated with the development of TAO among individuals with newly diagnosed GD. DESIGN, SETTING, AND PARTICIPANTS In this longitudinal cohort study, all beneficiaries 18 years of age or older with newly diagnosed GD who were continuously enrolled in a large nationwide US managed care network and who visited an eye care professional 1 or more times from 2001 to 2009 were identified. International Classification of Diseases, Ninth Revision, Clinical Modification billing codes were used to identify those who developed manifestations of TAO. Multivariable Cox regression was used to determine the hazard of developing TAO among persons with newly diagnosed GD, with adjustment for sociodemographic factors, systemic medical conditions, thyrotropin levels, and medical and surgical interventions for management of hyperthyroidism. MAIN OUTCOMES AND MEASURES Manifestations of TAO measured by hazard ratios (HRs) with 95% CIs. RESULTS Of 8404 patients with GD who met the inclusion criteria, 740 (8.8%) developed TAO (mean follow-up, 374 days since initial GD diagnosis). After adjustment for potential confounders, surgical thyroidectomy, alone or in combination with medical therapy, was associated with a 74% decreased hazard for TAO (adjusted HR, 0.26 [95% CI, 0.12-0.51]) compared with radioactive iodine therapy alone. Statin use (for >= 60 days in the past year vs < 60 days or nonuse) was associated with a 40% decreased hazard (adjusted HR, 0.60 [CI, 0.37-0.93]). No significant association was found for the use of nonstatin cholesterol-lowering medications or cyclooxygenase 2 inhibitors and the development of TAO. CONCLUSIONS AND RELEVANCE If prospective studies can confirm our finding that a thyroidectomy and statin use are associated with substantially reduced hazards for TAO among patients with GD, preventive measures for this burdensome manifestation of GD may become a reality.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.4
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据